| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.6 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | nakiterpiosin | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |